Primary Sjögren Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

44 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-09-30

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Sjögren syndrome (pSS) is an inflammatory, autoimmune, multiorgan disease often involving the central and peripheral nervous systems. Fifteen to twenty percent of patients with the primary Sjögren's syndrome have neurological complications involving the peripheral nervous system. Although some patients have large fiber neuropathy, around forty percent of patients with Sjögren's syndrome experience neuropathic pain with normal electrodiagnostic studies. Although these patients may be diagnosed with fibromyalgia or depressive symptoms, some have been shown to have small fiber neuropathy (SFN). A recent study proved that more than 90% of pSS patients with such neuropathic pain have SFN {Fauchais, 2010 #188}.

The aim of this study will be to investigate the occurrence of small fiber neuropathy in patients with pSS and neuropathic pain with normal electromyographic studies and to determine the existence of a conjoint local inflammatory process mediated by cellular, cytokinic or auto-antibody response. Quantification of epidermal nerve fiber density after skin biopsy is a valuable tool to diagnose small fiber neuropathy and the method has been widely validated. A skin biopsy will be performed in patients and control and will allow quantification of small fiber density in skin sample along with measurement of sweat gland innervation. Moreover, pathophysiological studies will be carried on in order to evaluate the causal relationship between cellular and humoral inflammation and small fiberneuropathy.

Recent studies have pointed out the inconstant efficacy of both corticosteroid and immunosuppressive drugs in pSS-related SFN. Dissecting the molecular mechanisms of small fiber neuropathy in these patients may help designing new therapeutic strategies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers in Primary Sjögren's Syndrome

NCT03765593

Primary Sjögren Syndrome Lymphoma, Non-Hodgkin

UNKNOWN

Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy

NCT03509064

Primary Sjögren Syndrome Small Fiber Neuropathy Quality of Life +1 more

RECRUITING

Efficacy of Tocilizumab in Primary Sjögren's Syndrome.

NCT01782235

Primary Sjögren's Syndrome (pSS)

COMPLETED PHASE2/PHASE3

Interstitial Lung Diseases in Primary Sjogren's Syndrome

NCT04978883

Sjogren's Syndrome

COMPLETED

Examining the Immunological Process of Autoimmune Patients

NCT02123147

Sjogren's Syndrome Autoimmune Diseases Dry Eyes +1 more

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Sjögren's Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with Sjögren's syndrome

A skin biopsy will be performed in patients

skin biopsy

Intervention Type OTHER

control group

A skin biopsy will be performed in control group

skin biopsy

Intervention Type OTHER

non auto-immune small fiber neuropathies

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

skin biopsy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with pSS according to revised European criteria and exhibiting neuropathic pain without any electromyographic abnormality will be included (Group I).
* Age of entry into the study ≥ 18 yrs (both groups).
* Affiliated or profit patient of a social security system (both groups).
* Informed consent signed up (both groups).

Exclusion Criteria

* Chronic alcoholism
* Type I or type II diabetes
* Peripheral neuropathy unrelated to pSS complications
* Coagulation disease
* Previous allergy to xylocaine, lidocaine, prilocaine or ricin oil
* Porphyria, methemoglobinemia
* Patients under measure of maintenance of justice.
* Patients unable to understand or to participate to the study.
* Child and major patients making the object of a measure of lawful protection.
* Patients deprived of freedom.
* Pregnant, nursing women.
* Participation in biomedical research within one month prior to inclusion.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes